Aerie Pharmaceuticals has acquired the rights to Envisia Therapeutics’ PRINT technology, according to an Aerie press release.
The PRINT technology system creates sustained-release products utilizing fully scalable manufacturing processes, the release said. Aerie plans to use it to “accelerate the advancement of its pipeline to treat conditions in the back of the eye,” including wet age-related macular degeneration and diabetic retinopathy.
Aerie initially will use the technology to make injectable implants containing AR-13154, its preclinical product candidate.
Additionally,
Uncategorized